OCT1 polymorphism is associated with response and survival time in anti-Parkinsonian drug users - Wikidata - awgldk - TriplyDB

OCT1 polymorphism is associated with response and survival time in anti-Parkinsonian drug users

OCT1 polymorphism is associated with response and survival time in anti-Parkinsonian drug users

http://www.wikidata.org/entity/Q34534509

about

Role of the plasma membrane transporter of organic cations OCT1 and its genetic variants in modern liver pharmacology Genetic analysis of OCT1 gene polymorphisms in an Indian population PharmGKB summary: very important pharmacogene information for SLC22A1 Identification of key pathways and transcription factors related to Parkinson disease in genome wide.The Rotterdam Study: 2012 objectives and design update.L-DOPA Uptake in Astrocytic Endfeet Enwrapping Blood Vessels in Rat Brain.Pharmacogenetics of Parkinson's disease - through mechanisms of drug actions.Distribution of genetic polymorphisms of genes encoding drug metabolizing enzymes & drug transporters - a review with Indian perspective.Parkinson's disease pharmacogenomics: new findings and perspectives.Pharmacogenetics of drug response in Parkinson's disease.The role of glia in stress: polyamines and brain disorders Pharmacogenetic considerations in the treatment of Parkinson's disease.Role of SLC22A1 polymorphic variants in drug disposition, therapeutic responses, and drug-drug interactions.Expression of organic cation transporter 1 (OCT1): unique patterns of indirect regulation by nuclear receptors and hepatospecific gene regulation.Impact of Transporter Polymorphisms on Drug Development: Is It Clinically Significant?Transporters as Drug Targets in Neurological Diseases Genetic polymorphisms of OCT-1 confer susceptibility to severe progression of primary biliary cirrhosis in Japanese patients.Genome-wide response to antihypertensive medication using home blood pressure measurements: a pilot study nested within the HOMED-BP study.Pharmacogenetics of neural injury recovery.Genetics and Treatment Response in Parkinson's Disease: An Update on Pharmacogenetic Studies.From Genomics to Omics Landscapes of Parkinson's Disease: Revealing the Molecular Mechanisms.Genetic Heterogeneity of SLC22 Family of Transporters in Drug Disposition.

P2860

Q27026858-1C86BAF8-77DC-4CA5-B82A-4926BA2242D1 Q28732156-E094AC01-5D01-4AF9-9D66-450E9E498186 Q33671763-8C45EA5F-35CD-4EC3-80C0-07FFAF40019C Q34449994-51C6EA75-632C-40E0-82CA-4D1213B4255A Q35201574-2104EB15-D5E2-4D8F-9F05-8C6B10A04220 Q36131925-47E8CAFF-AE18-454D-B23F-FE4DA8BEA095 Q37583417-4DD4B5F9-1C91-4B2D-B6EF-4DA14A0E4C7F Q37715233-5F68B6B8-9CD9-4785-9D65-E63D65250E0A Q38241678-B397AE6F-8B4B-4D41-A53A-41DBB82A079B Q38250117-79CD8F25-9CB8-49EF-B103-CD3425340CA6 Q38278661-1DB330E4-668A-48ED-87BB-BA95C507F951 Q38364825-F5FD9A54-F0A6-48B1-8A91-622A14822D08 Q38622785-DE546A8A-3DDE-4031-AA99-CABE868AC790 Q38859468-5E4D0738-6298-478B-8CEC-5E8BC117C46D Q38888369-E5611CFB-FAA0-41EC-B174-60C521308DBA Q38905608-2D5BFFAC-6F46-4E1B-83A9-0659A3BE5BB0 Q43672317-DC5D4686-D516-48F4-88E9-36886A0A3711 Q45224072-5793B7D3-B47C-4550-9690-E04379469DD1 Q46852529-BA74EEF6-37B5-4CF2-95C0-98932B0D4721 Q47648607-B813172A-4021-4350-B0C8-4661037A25B6 Q49197356-8FEC56F2-D256-476C-A4F6-62764DABAACA Q55514622-908A95A9-4FB8-445F-AD41-384E7BDB1571

P2860

OCT1 polymorphism is associated with response and survival time in anti-Parkinsonian drug users

http://www.wikidata.org/entity/Q34534509

description

2010 nî lūn-bûn

@nan

2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

OCT1 polymorphism is associate ...... n anti-Parkinsonian drug users

@ast

OCT1 polymorphism is associate ...... n anti-Parkinsonian drug users

@en

OCT1 polymorphism is associate ...... n anti-Parkinsonian drug users

@nl

type

label

OCT1 polymorphism is associate ...... n anti-Parkinsonian drug users

@ast

OCT1 polymorphism is associate ...... n anti-Parkinsonian drug users

@en

OCT1 polymorphism is associate ...... n anti-Parkinsonian drug users

@nl

prefLabel

OCT1 polymorphism is associate ...... n anti-Parkinsonian drug users

@ast

OCT1 polymorphism is associate ...... n anti-Parkinsonian drug users

@en

OCT1 polymorphism is associate ...... n anti-Parkinsonian drug users

@nl

P1433

Q34534509-DCDB046B-EDCA-4F43-A192-571AA84686E1

P1476

Q34534509-D5D653A5-E563-4538-88EC-6D52D2626CE1

P2093

Q34534509-2D2AA710-0CB7-4CF1-A803-2FF8A40A0AC2

Q34534509-7C50F6A8-48B6-42B2-8A1C-494DEA237114

Q34534509-A4673227-05C1-4A0D-AF6C-6E945904E883

Q34534509-F6203BC3-3800-46D5-8585-83A01D026303

P2860

Q34534509-0F3DFFD3-5198-4832-B4C6-25E3DCE069D0

Q34534509-22AE159E-C737-46D1-9302-EDE9F085AF9A

Q34534509-3AC44F1B-973E-4E26-BC8F-D4D9C15A149E

Q34534509-4067FFEC-E11B-4359-B91F-5B149A651D94

Q34534509-6741F4EB-5D21-4EAA-A645-0B06133B0294

Q34534509-7C306DB5-42D1-4E28-B309-9118FC53E12C

Q34534509-88D38D7A-167E-42D9-A8D1-A001E5252EAC

Q34534509-9B57A2FE-2605-4362-B348-A7E8274A0A45

Q34534509-9EEF2789-5178-4D6C-8837-5E184102CC35

Q34534509-B5DB4677-D4A5-4017-B425-B0ABF7768825

P2888

Q34534509-60283045-E1F2-4B14-B70E-FDFF0D29281E

P304

Q34534509-65B9C0FD-AFF1-41DF-82D7-9CE903E6A98E

P31

Q34534509-3E67144E-C709-4699-82DB-580ECCD29670

P356

Q34534509-D4978F77-D64F-434A-ACC6-9C4B1E149460

P433

Q34534509-0325A97F-77D8-45F2-8A3C-1DBDED5EE0F0

P478

Q34534509-7C464D2A-155C-4F56-A85A-8AC6B34CB541

P50

Q34534509-438C50BF-E4BE-4DAB-B772-D8912F24343F

Q34534509-6AB9AC5D-8A84-47A9-B896-7FBB9E676B94

P577

Q34534509-1C8EF946-D248-48A3-A0E3-A26A9AB7CEE5

P5875

Q34534509-FB8BE08D-BC63-4D50-8905-DFBF4AB7861F

P698

Q34534509-46B3CC2E-3DF0-4E9A-A1A6-F7C0205A4493

P921

Q34534509-969C2014-A724-4AFD-9951-836109237808

P932

Q34534509-DFF29ACA-0485-4CF5-8D7A-A52C92187300

P356

S10048-010-0254-5

P1433

P1476

OCT1 polymorphism is associate ...... n anti-Parkinsonian drug users

@en

P2093

Bruno H Ch Stricker

http://www.w3.org/2001/XMLSchema#string

Loes E Visser

http://www.w3.org/2001/XMLSchema#string

Matthijs L Becker

http://www.w3.org/2001/XMLSchema#string

Ron H N van Schaik

http://www.w3.org/2001/XMLSchema#string

P2860

The Rotterdam Study: 2010 objectives and design update

The International HapMap Project

Catecholamine transport by the organic cation transporter type 1 (OCT1)

Apical uptake of organic cations by human intestinal Caco-2 cells: putative involvement of ASF transporters.

Pharmacological and physiological functions of the polyspecific organic cation transporters: OCT1, 2, and 3 (SLC22A1-3).

Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications.

Blood-brain barrier transport of pramipexole, a dopamine D2 agonist.

The cation transporters rOCT1 and rOCT2 interact with bicarbonate but play only a minor role for amantadine uptake into rat renal proximal tubules.

Opossum kidney cells take up L-DOPA through an organic cation potential-dependent and proton-independent transporter.

Studies on the pharmacology of the inward transport of L-DOPA in rat renal tubules.

P2888

s10048-010-0254-5

P304

79-82

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10048-010-0254-5

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P50

André Uitterlinden

P577

2010-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

45462783

http://www.w3.org/2001/XMLSchema#string

P698

20680652

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease

P932

3029819

http://www.w3.org/2001/XMLSchema#string